PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

EC approves Ponvory for relapsing MS

The European Commission (EC) has cleared Janssen’s Ponvory for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease.
The European approval follows the recent announcement of the US Food and Drug Administration (FDA) approval of Ponvory (ponesimod) for RMS in March 2021.
The EC authorisation is based on data from the Phase III Optimum study, which was designed to evaluate the efficacy and safety of once daily oral Ponvory versus Sanfo’s once-daily MS treatment Aubagio (teriflunomide).
In this study, Ponvory demonstrated superior efficacy, with an annualised relapse rate (ARR) reduction of 30.5% compared with Aubagio.
Janssen’s drug also showed statistically significant superiority on one of the study’s secondary endpoints – combined with unique active lesions (CUALs).
Ponvory was found to significantly reduce the rate of new inflammatory lesion on brain MRI by 56% at week 108 compared with Sanofi’s drug.
The among of treatment-emergent adverse events reported in the Optimum study was also similar between the Ponvory and Aubagio treatment groups, with the majority of side effects being mild to moderate in nature and not causing treatment discontinuation.
“At Janssen, our mission is to reduce the burden, disability and devastation caused by diverse diseases of the central nervous system, including multiple sclerosis, for which there remains significant unmet patient need,” said Mathai Mammen, global head, Janssen Research & Development, Johnson & Johnson.
“The approval of [Ponvory] by the European Commission is a significant milestone as it showcases our continued commitment in neurology, reflecting our deepened focus and commitment to this space,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026